• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

模拟 Kv1.5 阻断对犬动作电位的影响。

Modeling the effect of Kv1.5 block on the canine action potential.

机构信息

Fraunhofer-Chalmers Centre, Chalmers Science Park, Göteborg, Sweden.

出版信息

Biophys J. 2010 Nov 3;99(9):2726-36. doi: 10.1016/j.bpj.2010.08.062.

DOI:10.1016/j.bpj.2010.08.062
PMID:21044569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2965949/
Abstract

A wide range of ion channels have been considered as potential targets for pharmacological treatment of atrial fibrillation. The Kv1.5 channel, carrying the I(Kur) current, has received special attention because it contributes to repolarization in the atria but is absent or weakly expressed in ventricular tissue. The dog serves as an important animal model for electrophysiological studies of the heart and mathematical models of the canine atrial action potential (CAAP) have been developed to study the interplay between ionic currents. To enable more-realistic studies on the effects of Kv1.5 blockers on the CAAP in silico, two continuous-time Markov models of the guarded receptor type were formulated for Kv1.5 and subsequently inserted into the Ramirez-Nattel-Courtemanche model of the CAAP. The main findings were: 1), time- and state-dependent Markov models of open-channel Kv1.5 block gave significantly different results compared to a time- and state-independent model with a downscaled conductance; 2), the outcome of Kv1.5 block on the macroscopic system variable APD(90) was dependent on the precise mechanism of block; and 3), open-channel block produced a reverse use-dependent prolongation of APD(90). This study suggests that more-complex ion-channel models are a prerequisite for quantitative modeling of drug effects.

摘要

已将多种离子通道视为治疗心房颤动的潜在药物靶点。Kv1.5 通道携带 I(Kur)电流,因其对心房复极有贡献,但在心室组织中缺失或表达较弱,故受到特别关注。犬是心脏电生理研究的重要动物模型,已开发出犬心房动作电位(CAAP)的数学模型,以研究离子电流之间的相互作用。为了能够在计算机上更真实地研究 Kv1.5 阻滞剂对 CAAP 的影响,我们针对 Kv1.5 构建了两种连续时间 Markov 门控受体模型,并随后将其插入 Ramirez-Nattel-Courtemanche 型 CAAP 模型中。主要发现包括:1)与采用缩小电导的时变和状态无关模型相比,时变和状态依赖的开放通道 Kv1.5 阻滞的 Markov 模型给出了显著不同的结果;2)Kv1.5 阻滞对宏观系统变量 APD(90)的影响取决于阻滞的精确机制;3)开放通道阻滞导致 APD(90)出现反向使用依赖性延长。本研究表明,更复杂的离子通道模型是定量药物效应建模的前提。

相似文献

1
Modeling the effect of Kv1.5 block on the canine action potential.模拟 Kv1.5 阻断对犬动作电位的影响。
Biophys J. 2010 Nov 3;99(9):2726-36. doi: 10.1016/j.bpj.2010.08.062.
2
Genetic ablation or pharmacological inhibition of Kv1.1 potassium channel subunits impairs atrial repolarization in mice.基因敲除或药理学抑制 Kv1.1 钾通道亚基可损害小鼠心房复极。
Am J Physiol Cell Physiol. 2019 Feb 1;316(2):C154-C161. doi: 10.1152/ajpcell.00335.2018. Epub 2018 Nov 14.
3
Inhibitory effects of hesperetin on Kv1.5 potassium channels stably expressed in HEK 293 cells and ultra-rapid delayed rectifier K(+) current in human atrial myocytes.橙皮素对稳定表达于HEK 293细胞中的Kv1.5钾通道及人心房肌细胞超快速延迟整流钾电流的抑制作用。
Eur J Pharmacol. 2016 Oct 15;789:98-108. doi: 10.1016/j.ejphar.2016.07.015. Epub 2016 Jul 7.
4
Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.Kv1.5是犬心房肌细胞复极化钾电流的重要组成部分。
Circ Res. 2003 Oct 17;93(8):744-51. doi: 10.1161/01.RES.0000096362.60730.AE. Epub 2003 Sep 18.
5
Revealing kinetics and state-dependent binding properties of I-targeting drugs that maximize atrial fibrillation selectivity.揭示靶向 I 通道药物的动力学和状态依赖性结合特性,以最大限度地提高心房颤动选择性。
Chaos. 2017 Sep;27(9):093918. doi: 10.1063/1.5000226.
6
Presence and functional role of the rapidly activating delayed rectifier K(+) current in left and right atria of adult mice.成年小鼠左右心房中快速激活延迟整流钾(K+)电流的存在和功能作用。
Eur J Pharmacol. 2010 Dec 15;649(1-3):14-22. doi: 10.1016/j.ejphar.2010.08.025. Epub 2010 Sep 6.
7
Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5.抗心律失常药物诱导的心房特异性钾通道Kv1.5的内化
Circ Res. 2009 Jun 19;104(12):1390-8. doi: 10.1161/CIRCRESAHA.108.192773. Epub 2009 May 14.
8
Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.XEN-D0101 的人体电生理学和药理学特性:一种新型心房选择性 Kv1.5/IKur 抑制剂。
J Cardiovasc Pharmacol. 2013 May;61(5):408-15. doi: 10.1097/FJC.0b013e31828780eb.
9
Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.新型、强效的人类Kv1.5钾通道抑制剂及超快速激活延迟整流钾电流。
J Pharmacol Exp Ther. 2006 Jun;317(3):1054-63. doi: 10.1124/jpet.106.101162. Epub 2006 Mar 7.
10
Rotor termination is critically dependent on kinetic properties of I kur inhibitors in an in silico model of chronic atrial fibrillation.转子终止在慢性心房颤动的计算机模型中严重依赖于 Ikur 抑制剂的动力学特性。
PLoS One. 2013 Dec 20;8(12):e83179. doi: 10.1371/journal.pone.0083179. eCollection 2013.

引用本文的文献

1
Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies.糖尿病中的心房颤动:发病机制与靶向性节律控制策略
Curr Issues Mol Biol. 2025 Jul 17;47(7):559. doi: 10.3390/cimb47070559.
2
A computational method for identifying an optimal combination of existing drugs to repair the action potentials of SQT1 ventricular myocytes.一种计算方法,用于确定现有药物的最佳组合,以修复 SQT1 心室肌细胞的动作电位。
PLoS Comput Biol. 2021 Aug 12;17(8):e1009233. doi: 10.1371/journal.pcbi.1009233. eCollection 2021 Aug.
3
Understanding the Beat-to-Beat Variations of P-Waves Morphologies in AF Patients During Sinus Rhythm: A Scoping Review of the Atrial Simulation Studies.理解房颤患者窦性心律时P波形态的逐搏变化:心房模拟研究的范围综述
Front Physiol. 2019 Jun 18;10:742. doi: 10.3389/fphys.2019.00742. eCollection 2019.
4
Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin.钠通道阻滞剂与金合欢素联合使用对人心房的协同抗心律失常作用
Front Physiol. 2017 Nov 23;8:946. doi: 10.3389/fphys.2017.00946. eCollection 2017.
5
In silico assessment of genetic variation in KCNA5 reveals multiple mechanisms of human atrial arrhythmogenesis.KCNA5基因变异的计算机模拟评估揭示了人类房性心律失常发生的多种机制。
PLoS Comput Biol. 2017 Jun 16;13(6):e1005587. doi: 10.1371/journal.pcbi.1005587. eCollection 2017 Jun.
6
Rate-Dependent Role of I in Human Atrial Repolarization and Atrial Fibrillation Maintenance.I在人体心房复极及心房颤动维持中的频率依赖性作用。
Biophys J. 2017 May 9;112(9):1997-2010. doi: 10.1016/j.bpj.2017.03.022.

本文引用的文献

1
Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1.Kv1.5 通道被二苯膦氧-1 阻断的分子决定因素。
J Mol Cell Cardiol. 2010 Jun;48(6):1111-20. doi: 10.1016/j.yjmcc.2010.02.010. Epub 2010 Feb 23.
2
I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.用于治疗心房颤动的I(Kur)/Kv1.5通道阻滞剂
Expert Opin Investig Drugs. 2009 Apr;18(4):399-416. doi: 10.1517/13543780902762850.
3
A note on a method for determining advantageous properties of an anti-arrhythmic drug based on a mathematical model of cardiac cells.
Math Biosci. 2009 Feb;217(2):167-73. doi: 10.1016/j.mbs.2008.12.001. Epub 2008 Dec 24.
4
Multiscale modelling of drug-induced effects on cardiac electrophysiological activity.药物对心脏电生理活动影响的多尺度建模
Eur J Pharm Sci. 2009 Jan 31;36(1):62-77. doi: 10.1016/j.ejps.2008.09.013. Epub 2008 Nov 17.
5
In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling.关于IKur阻滞动力学对房颤诱导的电重构后人动作电位延长影响的计算机模拟研究
Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H793-800. doi: 10.1152/ajpheart.01229.2007. Epub 2007 Nov 30.
6
Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.结构不同的IKur阻滞剂3-[(二甲氨基)甲基]-6-甲氧基-2-甲基-4-苯基异喹啉-1(2H)-酮和2-苯基-1,1-二吡啶-3-基-2-吡咯烷-1-基乙醇对伴有潜在心力衰竭犬的心房抗纤颤作用
J Pharmacol Exp Ther. 2008 Jan;324(1):322-30. doi: 10.1124/jpet.107.127654. Epub 2007 Oct 29.
7
SBaddon: high performance simulation for the Systems Biology Toolbox for MATLAB.SBaddon:用于MATLAB系统生物学工具箱的高性能模拟。
Bioinformatics. 2007 Mar 1;23(5):646-7. doi: 10.1093/bioinformatics/btl668. Epub 2007 Jan 18.
8
Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers.
Bioorg Med Chem Lett. 2006 Dec 15;16(24):6213-8. doi: 10.1016/j.bmcl.2006.09.021. Epub 2006 Sep 28.
9
Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.一种新型Kv1.5阻滞剂的结合位点:房颤治疗的“敲门砖”
Mol Pharmacol. 2006 Oct;70(4):1204-11. doi: 10.1124/mol.106.026203. Epub 2006 Jul 11.
10
Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.新型、强效的人类Kv1.5钾通道抑制剂及超快速激活延迟整流钾电流。
J Pharmacol Exp Ther. 2006 Jun;317(3):1054-63. doi: 10.1124/jpet.106.101162. Epub 2006 Mar 7.